Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
Lexaria Bioscience has announced the receipt of two new US patents in the medical fields of hypertension and epilepsy. The first patent, part of Lexaria's patent family #21, focuses on compositions and methods for treating hypertension using DehydraTECH-processed cannabidiol (CBD). The second patent, part of patent family #24, pertains to treating epilepsy, highlighting DehydraTECH-CBD's efficacy in mitigating epileptic seizures and its superior absorption compared to Epidiolex. Both patents are valid until 2042. Lexaria now holds a total of 43 patents globally, reinforcing its strategic business objectives.
- Two new US patents granted in hypertension and epilepsy.
- Patent for hypertension treatment valid until 2042.
- Hypertension patent demonstrates DehydraTECH-CBD's ability to lower blood pressure.
- Patent for epilepsy treatment valid until 2042.
- Epilepsy patent shows DehydraTECH-CBD's superior absorption compared to Epidiolex.
- Lexaria's patent portfolio now comprises 43 patents worldwide.
- No immediate financial impact reported from new patents.
- Clinical efficacy only demonstrated in rodents, not yet in human trials.
- Potential challenges in commercializing patented technologies may arise.
Insights
Lexaria Bioscience's new patents in the fields of hypertension and epilepsy are significant due to the potential implications for both medical treatment and the company's business prospects. The key innovation here is the use of their proprietary DehydraTECH technology, which has shown promise in improving the delivery and efficacy of cannabidiol (CBD) for these conditions.
For hypertension, DehydraTECH-CBD's ability to lower blood pressure both in acute and prolonged settings speaks to its potential as a more effective treatment compared to existing medications. This could open doors to new revenue streams, especially given the high prevalence of hypertension globally.
In epilepsy, the comparison to Epidiolex®, a leading cannabinoid-based anti-seizure medication, is particularly noteworthy. DehydraTECH-CBD's improved absorption could lead to better patient outcomes, making it a compelling alternative in a market that is always on the lookout for more effective treatments.
The patents solidify Lexaria's intellectual property position until 2042, offering a substantial time frame to capitalize on these innovations.
The granting of these patents significantly strengthens Lexaria's intellectual property (IP) portfolio, now totaling 43 worldwide patents. This robust IP framework is important for maintaining competitive advantage and protecting their proprietary technology. The patents' expiration dates in 2042 provide a long runway for Lexaria to develop and commercialize their treatments without immediate fear of generic competition.
Additionally, the specificity of these patents in both hypertension and epilepsy ensures that Lexaria can explore licensing opportunities with pharmaceutical companies looking to enter these therapeutic areas with proven cannabinoid-based treatments. This could potentially lead to lucrative partnerships and collaborations.
From an investor's perspective, a strong patent portfolio not only secures future revenue streams but also enhances the company's valuation and attractiveness as an acquisition target.
The cardiovascular and neurological drug markets are both lucrative and competitive. Hypertension affects millions globally, creating a substantial market opportunity for effective treatments. The epilepsy drug market is also significant, with an increasing demand for more effective therapies with fewer side effects.
Lexaria's DehydraTECH-CBD technology has the potential to tap into these markets by offering improved efficacy and absorption. This could translate to higher adoption rates among healthcare providers and patients, driving revenue growth. The fact that the company is targeting well-established, large-scale markets is a positive indicator for long-term business sustainability.
Moreover, the addition of these patents enhances Lexaria's market position and improves its chances of securing partnerships or licensing deals. The company's ability to continually innovate and expand its patent portfolio is a strong signal of its growth potential.
KELOWNA, BC / ACCESSWIRE / May 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces two important new patent awards.
The Company has received a new granted patent in Lexaria's patent family #21: Compositions and Methods for Treating Hypertension. This is the Company's third granted US patent in this patent family. As Lexaria has repeatedly demonstrated, DehydraTECH-processed cannabidiol ("CBD") has evidenced an ability to lower blood pressure in both acute dosing in hypertension as well as over a 5-week study duration. This patent will expire in 2042 if not extended.
The Company has also received a new granted patent in Lexaria's patent family #24: Compositions and Methods for Treating Epilepsy. This is the Company's third granted US patent in this patent family. This patent complements earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex®. This patent will expire in 2042 if not extended.
With the issuance of these two new patents, Lexaria's patent portfolio has now grown to 43 granted patents worldwide. Lexaria's intellectual property remains a significant component in supporting future business objectives.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 43 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
FAQ
What recent patents has Lexaria received?
When do Lexaria's new patents expire?
How many patents does Lexaria Bioscience hold?
What is DehydraTECH-CBD's role in Lexaria's new hypertension patent?
What advantage does DehydraTECH-CBD have over Epidiolex in epilepsy treatment?
